Latest GILD news and sentiment

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this HIV and hepatitis C drugmaker have returned +0.1% over the past month versus the Zacks S&P 500 composite's -2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has gained 1.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company'

Gilead Sciences Inc's Dividend Analysis

This article first appeared on GuruFocus. A Comprehensive Look at the Biopharma Giant's Upcoming Payout, Yield, and Long-Term Dividend Sustainability Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment. As investors look forward to this upcoming payment, the spotlight also sh

Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?

Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that market value lines up with what the business is generating in sales. The share price is up 146.6% over 5 years, which puts real pressure on the current sales base to justify where the stock now trades. The new Foster City research center and ongoing work in oncology and HIV therapies can shape how quickly revenue grows and how much

Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administr

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Gilead Sciences (GILD) closed at $146.64, marking a -2.88% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%. Shares of the HIV and hepatitis C drugmaker have appreciated by 13.48% over the course of the past month, outperforming the Medical sector's gain of 2.73%, and the S&P 500's loss of 0.36%. The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upco

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Assembly Biosciences, Inc. – Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it has exercised its option to share 40% of the development costs and profi

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

– Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration – – One of Three Foster City Projects Supporting Gilead's $32 Billion U.S. Investment and 3,000 High-Quality Domestic Jobs – FOSTER CITY, Calif., September 08, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the world's most challenging diseases. The new Research Cen

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Quick Read GILD's $10 billion in 2025 free cash flow covered its $4 billion dividend twice over, earning a B+ dividend safety grade. Patent settlements pushed the earliest generic Biktarvy entry to April 2036, giving Gilead a decade-long runway to diversify revenue before the cliff hits. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut. Income investors own Gilead Sciences (NASDAQ:GILD) for the check that lands every quarter. That check just got bigger, and

Can Bixlenvo Unlock New Growth for Gilead's HIV Business?

Gilead Sciences, Inc. GILD recently won FDA approval for Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval makes Bixlenvo the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. Bixlenvo combines bictegravir, a guideline-recommended integrase strand transfer inhibitor with a high barrier to resistance, and lenacapavir, a first-in-class capsid inhibitor with a novel mechanis

Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gilead Sciences (GILD). Gilead currently has an average brokerage recommendation (ABR) of 1.52, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recom

Gilead once-daily HIV pill approved in U.S.

[Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials] Justin Sullivan/Getty Images News The U.S. Food and Drug Administration has approved Gilead Sciences’ (GILD [https://seekingalpha.com/symbol/GILD]) oral once-daily antiviral Bixlenvo as the smallest single-tablet regimen for the treatment of HIV in adults. A combination of Gilead’s (GILD [https://seekingalpha.com/symbol/GILD]) once-daily HIV pill bictegravir and its twice-yearly pre-exposure prophylaxis option lenacapavir, Bixlenvo will therefore be available to treat HIV in virologica

Director de Gilead Sciences Welters vende acciones por 2,68 millones de dólares

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

FOSTER CITY, Calif., August 26, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday, September 9 at 11:00 AM Eastern Time Cantor Global Healthcare Conference on Thursday, September 10 at 10:55 AM Eastern Time Morgan Stanley Global Healthcare Conference on Tuesday, September 15 at 10:45 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days f